Medincell SA (MDCLF)
Market Closed
7 Aug, 13:30
$
34. 39
0
0%
$
1.23B Market Cap
- P/E Ratio
- Div Yield
21,644 Volume
0 Eps
$ 34.39
Previous Close Want to track MDCLF and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
MDCLF closed Friday higher at $34.39, an increase of 0% from Thursday's close, completing a monthly increase of 0% or $0. Over the past 12 months, MDCLF stock gained 392.9759%.
MDCLF is not paying dividends to its shareholders.
The last earnings report, released on Dec 09, 2025, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
Medincell SA has completed 1 stock splits, with the recent split occurring on Mar 16, 2017.
The company's stock is traded on 8 different exchanges and in various currencies, with the primary listing on XPAR (EUR).
Medincell SA (MDCLF) FAQ
What is the stock price today?
The current price is $34.39.
On which exchange is it traded?
Medincell SA is listed on OTC PINK.
What is its stock symbol?
The ticker symbol is MDCLF.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 1.23B.
Has Medincell SA ever had a stock split?
Medincell SA had 1 splits and the recent split was on Mar 16, 2017.
Medincell SA Profile
| Biotechnology Industry | Healthcare Sector | Christophe Douat CEO | OTC PINK Exchange | FR0004065605 ISIN |
| FR Country | 131 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
MedinCell S.A. is a pioneering pharmaceutical company based in Jacou, France, with a focus on the development of long-acting injectables across a variety of therapeutic domains. Leveraging its proprietary BEPO technology, MedinCell aims to transform the delivery of medicines by developing solutions that ensure sustained drug release. This innovative approach not only enhances patient compliance by reducing the frequency of dosages but also promises to improve overall treatment outcomes. Founded in 2003, the company has established itself as a leader in the field, working towards addressing some of the most pressing medical needs with its cutting-edge technology.
Products and Services
MedinCell's product pipeline is rich and diversified, encompassing a range of treatments in various stages of development:
- mdc-IRM: This is a risperidone extended-release injectable suspension, being developed for the treatment of schizophrenia in adults. By offering a long-acting formulation, mdc-IRM aims to improve adherence and outcomes for patients managing this complex condition.
- mdc-CWM: Currently in Phase III trials, mdc-CWM is a sustained-release formulation of celecoxib. It's designed for the reduction of postoperative pain and inflammation, potentially revolutionizing pain management protocols in surgical settings.
- mdc-TJK: Also in Phase III clinical trials, mdc-TJK is a subcutaneous injection formulated to treat schizophrenia. The development of mdc-TJK underscores MedinCell's commitment to addressing mental health issues with innovative, lasting solutions.
- Preclinical Trials: A suite of product candidates is in preclinical testing, highlighting MedinCell's research and innovation depth. These include:
- mdc-ANG: An antipsychotic product aimed at treating schizophrenia, expanding MedinCell's portfolio in mental health.
- mdc-TTG: A development for the treatment of Covid-19 and its variants, demonstrating MedinCell's flexibility in addressing emergent global health crises.
- mdc-GRT: Focused on organ transplant patients, mdc-GRT is being developed to improve transplant outcomes and patient quality of life.
- mdc-WWM: This contraceptive product underlines MedinCell's commitment to providing long-term solutions in reproductive health.
- mdc-STM: Aiming at the prevention and treatment of malaria, mdc-STM reflects MedinCell's dedication to tackling infectious diseases that have a profound impact on global health.
- mdc-IRM in neuroscience: Furthering their expertise in neuroscience, this development focuses on leveraging BEPO technology for various neurological applications.
Contact Information
Address: 3 rue des Frères Lumière
Phone: 33 4 67 02 13 67
Website: https://www.medincell.com
